yingweiwo

Zolmitriptan

Alias: 311C 90; Flezol; zolmitriptan; 311C90; 311 C90; trade names Zomig; Zomigon; AscoTop; Zomigoro
Cat No.:V0989 Purity: ≥98%
Zolmitriptan (311C90; 311 C90; trade names AscoTop, Zomig, Zomigon, Zomigoro), an approved drug for the treatment of acute migraines, is a potent and highly selective 5-HT(1B/1D) receptor agonist of the triptan class.
Zolmitriptan
Zolmitriptan Chemical Structure CAS No.: 139264-17-8
Product category: 5-HT Receptor
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
250mg
500mg
1g
2g
5g
10g
Other Sizes
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text

 

  • Business Relationship with 5000+ Clients Globally
  • Major Universities, Research Institutions, Biotech & Pharma
  • Citations by Top Journals: Nature, Cell, Science, etc.
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Zolmitriptan (311C90; 311 C90; trade names AscoTop, Zomig, Zomigon, Zomigoro), an approved drug for the treatment of acute migraines, is a potent and highly selective 5-HT(1B/1D) receptor agonist of the triptan class.

Biological Activity I Assay Protocols (From Reference)
Targets
5-HT1B Receptor ( IC50 = 5.01 nM ); 5-HT1D Receptor ( IC50 = 0.63 nM ); 5-HT1F Receptor ( IC50 = 63.09 nM ); Human Endogenous Metabolite
ln Vitro

In vitro activity: Zolmitriptan causes the human epicardial coronary artery rings and the primate basilar artery to contract in response to concentration. High affinity for human recombinant 5-HT1D (previously 5-HT1D alpha) and 5-HT1B (previously 5-HT1D beta) receptors is demonstrated by zolmitriptan in transfected CHO-K1 cell membranes.[1] With a pD(2) value of 7.03, zolmitriptan raises I(K) in C6 glioma cells expressing recombinant human 5-HT(1B) receptor in a concentration-dependent manner, reaching a maximum increase of 16.3%. When added to the patch pipette in C6 cells expressing cloned human 5-HT(1B) receptors, the calcium chelator EGTA (5 mM) inhibits zolmitriptan-induced increases in I(K).[2]

ln Vivo
Zolmitriptan (3-30 mg/kg, i.v.) administered ten minutes prior to unilateral electrical stimulation of the trigeminal ganglion results in a dose-dependent inhibition of [125I]-albumin extravasation within the ipsilateral dura mater in anaesthetized guinea-pigs.[1] Zolmitriptan (10-1000 mg/kg, i.v.) reduces arteriovenous-anastomotic (AVA) conductance in a targeted manner, with a maximum reduction of 92.5%. While zolmitriptan has no effect on cerebral conductance, it does produce a slight reduction in extra-cerebral conductance (maximum reduction of 23.9% at 30 mg/kg, i.v.). In anesthetized cats, zolmitriptan (1-30 mg/kg, intravenously) causes dose-dependent reductions in ear microvascular conductance (15% to 60%), which are mirrored by reductions in carotid arterial conductance.[3] In mice, zolmitriptan has anti-aggressive effects that are behaviorally specific. Moreover, zolmitriptan equally effectively reduces alcohol-induced aggression in mice.[4]
Animal Protocol
Anaesthetized guinea-pigs
0, 3, 10, 30 μg/kg
I.v.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Zolmitriptan tablets have a mean absolute oral bioavailability of approximately 40%, with food having no effect on the rate or extent of absorption. The dosing kinetics are linear over a range of 2.5 to 50 mg with 75% of the eventual Cmax being attained within 1 hour of dosing. The median Tmax for the tablet form is 1.5 hours, while for the orally disintegrating tablet form, it is 3 hours. The AUC across studies was in the range of 84.4-173.8 ng/mL*h while the Cmax was between 16 and 25.2 ng/mL. Zolmitriptan administered as a nasal spray is detected in the plasma within 2-5 minutes, compared to 10-15 minutes for the tablet form; the faster kinetics likely reflect fast absorption across the nasal mucosa. The bioavailability compared to the tablet is 102%, and plasma zolmitriptan concentration is maintained for 4-6 hours after intranasal delivery. The active N-desmethyl metabolite of zolmitriptan has a mean plasma concentration that is roughly two-thirds of zolmitriptan, regardless of dosage route or concentration.
Zolmitriptan is primarily excreted in urine (approximately 65%) and feces (approximately 30%). Within urine, the most common form is the indole acetic acid metabolite (31%), followed by the N-oxide (7%), and N-desmethyl (4%) metabolites; the majority of zolmitriptan recovered in feces remains unchanged.
Zolmitriptan has a volume of distribution between 7 and 8.4 L/kg.
Zolmitriptan has a clearance of 31.5 mL/min/kg for oral tablets and 25.9 mL/min/kg for nasal administration; one-sixth of the clearance is renal.
Metabolism / Metabolites
Zolmitriptan is metabolized in the liver, and studies using cytochrome P450 inhibitors like [cimetidine] suggest that it is likely metabolized by CYP1A2, as well as by monoamine oxidase (MAO). Zolmitriptan metabolism results in three major metabolites: an active N-desmethyl metabolite (183C91) as well as inactive N-oxide (1652W92) and indole acetic acid (2161W92) metabolites.
Zolmitriptan has known human metabolites that include Zolmitriptan N-oxide and N-Desmethylzolmitriptan.
Hepatic. There have been three metabolites identified: indole acetic acid, N -oxide, and N-desmethyl metabolites. However, the N-desmethyl is the only active metabolite.
Half Life: The mean elimination half-life of zolmitriptan and of the active N-desmethyl metabolite is 3 hours.
Biological Half-Life
Zolmitriptan has a mean elimination half-life of approximately three hours following oral or nasal administration. Its active N-desmethyl metabolite has a slightly longer (approximately 3.5 hours) half-life.
Toxicity/Toxicokinetics
Toxicity Summary
Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Preliminary evidence indicates that zolmitriptan levels in breastmilk are low. Amounts ingested by the infant are small and unlikely to affect the nursing infant, especially if the infant is older than 2 months. Concurrent use of propranolol might increase the zolmitriptan dose received by the breastfed infant substantially. Painful, burning nipples and breast pain have been reported after doses of sumatriptan and other triptans. This has occasionally been accompanied by a decrease in milk production.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
A review of four European adverse reaction databases found 26 reported cases of, painful, burning nipples, painful breasts, breast engorgement and/or painful milk ejection in women who took a triptan while nursing. Pain was sometimes intense and occasionally led to decreased milk production. Pain generally subsided with time as the drug was eliminated. The authors proposed that triptans may cause vasoconstriction of the arteries in the breast, nipples, and the arteries surrounding the alveoli and milk ducts, causing a painful sensation and a painful milk ejection reflex.
Protein Binding
Zolmitriptan and its active N-desmethyl metabolite remain approximately 25% bound to plasma proteins over a concentration range of 10-1000 ng/mL.
References

[1]. Br J Pharmacol . 1997 May;121(2):157-64.

[2]. Eur J Pharmacol . 2000 Jun 2;397(2-3):297-302.

[3]. Eur J Pharmacol . 1998 Nov 20;361(2-3):191-7.

[4]. Psychopharmacology (Berl) . 2001 Sep;157(2):131-41.

Additional Infomation
Pharmacodynamics
Zolmitriptan, like other triptans, is a serotonin (5-hydroxytryptamine; 5-HT) receptor agonist, with enhanced specificity for the 5-HT1B and 5-HT1D receptor subtypes. It is through the downstream effects of 5-HT1B/1D activation that triptans are proposed to provide acute relief of migraines. Zolmitriptan is also a vasoconstrictor, leading to possible adverse cardiovascular effects such as myocardial ischemia/infarction, arrhythmias, cerebral and subarachnoid hemorrhage, stroke, gastrointestinal ischemia, and peripheral vasospastic reactions. In addition, chest/throat/neck/jaw pain, tightness, and/or pressure has been reported, along with the possibility of medication overuse headaches and serotonin syndrome. Patients with phenylketonuria should be advised that ZOMIG-ZMT contains phenylalanine.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C16H21N3O2
Molecular Weight
287.36
Exact Mass
287.163
Elemental Analysis
C, 66.88; H, 7.37; N, 14.62; O, 11.14
CAS #
139264-17-8
Related CAS #
139264-17-8
PubChem CID
60857
Appearance
White to off-white solid powder
Density
1.2±0.1 g/cm3
Boiling Point
563.3±38.0 °C at 760 mmHg
Melting Point
136-141ºC
Flash Point
294.5±26.8 °C
Vapour Pressure
0.0±1.5 mmHg at 25°C
Index of Refraction
1.620
LogP
1.64
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
3
Rotatable Bond Count
5
Heavy Atom Count
21
Complexity
375
Defined Atom Stereocenter Count
1
SMILES
O1C(N([H])[C@]([H])(C1([H])[H])C([H])([H])C1C([H])=C([H])C2=C(C=1[H])C(=C([H])N2[H])C([H])([H])C([H])([H])N(C([H])([H])[H])C([H])([H])[H])=O
InChi Key
ULSDMUVEXKOYBU-ZDUSSCGKSA-N
InChi Code
InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1
Chemical Name
(4S)-4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
Synonyms
311C 90; Flezol; zolmitriptan; 311C90; 311 C90; trade names Zomig; Zomigon; AscoTop; Zomigoro
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 58~100 mg/mL (201.8~348.0 mM)
Water: <1 mg/mL
Ethanol: ~58 mg/mL (~201.8 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (8.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

View More

Solubility in Formulation 3: 2.5 mg/mL (8.70 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.4800 mL 17.3998 mL 34.7996 mL
5 mM 0.6960 mL 3.4800 mL 6.9599 mL
10 mM 0.3480 mL 1.7400 mL 3.4800 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05019430 Recruiting Drug: Zolmitriptan
Drug: Cocaine
Cocaine Use Disorder William Stoops October 15, 2021 Early Phase 1
NCT03145467 Completed Drug: Paracetamol
Drug: Zolmitriptan
Acute Migraine Headache Pamukkale University January 2016 Phase 4
NCT02745392 Completed Drug: ZP-Zolmitriptan
Drug: Placebo
Acute Migraine Zosano Pharma Corporation June 2016 Phase 2
Phase 3
NCT00637286 Completed Drug: Zolmitriptan Migraine AstraZeneca July 2004 Phase 4
NCT00617747 Completed Drug: Zolmitriptan
Drug: Placebo
Migraine AstraZeneca September 2002 Phase 3
Contact Us